Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced concerning side effects like throat irritation, shortness of breath, chest pain, and testicle pain after using RU58841 for hair loss, despite also using finasteride and minoxidil. Other users shared mixed experiences, with one advising to stop using RU58841 due to similar side effects, while another reported significant hair loss reduction without side effects.

Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

The conversation discusses avoiding caffeine after Platelet-Rich Plasma (PRP) treatment for hair loss because caffeine is a vasoconstrictor, which can reduce blood flow and hinder the healing process that PRP aims to promote.

Revivhair serum is discussed as a potential treatment for mild hair thinning, but skepticism exists about its effectiveness without proven treatments like finasteride, dutasteride, or minoxidil. Users share experiences with various treatments, noting side effects and exploring alternatives like topical dutasteride and alfatradiol.

Kintor KX-826, a hair loss treatment, is being discussed for its pricing and effectiveness, with a focus on whether the 0.9% concentration is more effective than the 0.5%. Users are seeking cheaper purchasing options.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A user confirmed that koshinemall.com is the official site for buying Pyrilutamide after contacting Kintor directly. They expressed initial skepticism due to the website's quality and phone number requirement.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

The user did not respond to minoxidil and is considering using tretinoin to improve results. They also explored finasteride, microneedling, adapalene, red light therapy, and oral minoxidil as potential treatments.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.

The conversation is about choosing an additional topical treatment for hair loss, with options being fluridil, topical spiro, or alfatradiol, alongside existing treatments like dutasteride, oral minoxidil, latanoprost, and RU58841. Opinions vary on the effectiveness of adding these topicals, with some suggesting RU58841 is sufficient.

A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation is about different treatments for hair loss, including minoxidil, finasteride, RU58841, and dermarolling. The conclusion is that RU58841 and dermarolling have shown efficacy in treating hair loss through different pathways.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.

High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

The conversation discusses hair loss treatments, specifically the use of finasteride, dutasteride, and RU58841. The user is seeking alternatives after finasteride failed to stop hair loss, with suggestions to try dutasteride or consider RU58841 under caution.

Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

A user discussed their hair transplant progress and mentioned using 1mg Finasteride, 5% Topical Minoxidil, and recently starting 5% RU58841. They are seeking advice on whether to use RU58841 at month 4 post-transplant.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.

RU58841 is discussed as a potential hair loss treatment. Minoxidil and finasteride are also mentioned as common treatments.